1 |
TNFSF13B
| 4件: Cytokine-cytokine receptor interaction Cytokine-cytokine receptor interaction, NF-kappa B signaling pathway, Intestinal immune network for IgA production, Rheumatoid arthritis | D03068
D03068
|
Belimumab
| 13件: 11 11, 13, 43, 44, 46, 49, 51, 53, 63, 66, 222, 296, 300 |
2 |
CSF3R
| 5件: Cytokine-cytokine receptor interaction Cytokine-cytokine receptor interaction, PI3K-Akt signaling pathway, JAK-STAT signaling pathway, Hematopoietic cell lineage, Pathways in cancer | D03235
D03235
|
Filgrastim
| 35件: 2 2, 6, 11, 13, 16, 22, 25, 26, 28, 34, 35, 36, 38, 40, 41, 42, 45, 46, 47, 49, 51, 57, 60, 62, 65, 85, 96, 113, 164, 256, 283, 284, 285, 296, 331 |
3 |
ADRA1D
| 6件: Calcium signaling pathway Calcium signaling pathway, cGMP-PKG signaling pathway, Neuroactive ligand-receptor interaction, Adrenergic signaling in cardiomyocytes, Vascular smooth muscle contraction, Salivary secretion | D00076
D00076
|
Norepinephrine
| 2件: 22 22, 296 |
4 |
ADRA1B
| 6件: Calcium signaling pathway Calcium signaling pathway, cGMP-PKG signaling pathway, Neuroactive ligand-receptor interaction, Adrenergic signaling in cardiomyocytes, Vascular smooth muscle contraction, Salivary secretion | D00076
D00076
|
Norepinephrine
| 2件: 22 22, 296 |
5 |
ADRA1A
| 7件: Calcium signaling pathway Calcium signaling pathway, cGMP-PKG signaling pathway, Neuroactive ligand-receptor interaction, AMPK signaling pathway, Adrenergic signaling in cardiomyocytes, Vascular smooth muscle contraction, Salivary secretion | D00076
D00076
|
Norepinephrine
| 2件: 22 22, 296 |
6 |
ADRA2A
| 2件: cGMP-PKG signaling pathway cGMP-PKG signaling pathway, Neuroactive ligand-receptor interaction | D00076
D00076
|
Norepinephrine
| 2件: 22 22, 296 |
7 |
ADRA2B
| 2件: cGMP-PKG signaling pathway cGMP-PKG signaling pathway, Neuroactive ligand-receptor interaction | D00076
D00076
|
Norepinephrine
| 2件: 22 22, 296 |
8 |
ADRA2C
| 2件: cGMP-PKG signaling pathway cGMP-PKG signaling pathway, Neuroactive ligand-receptor interaction | D00076
D00076
|
Norepinephrine
| 2件: 22 22, 296 |
9 |
ADRB1
| 11件: Calcium signaling pathway Calcium signaling pathway, cGMP-PKG signaling pathway, cAMP signaling pathway, Neuroactive ligand-receptor interaction, Adrenergic signaling in cardiomyocytes, Gap junction, Regulation of lipolysis in adipocytes, Renin secretion, Salivary secretion, Chemical carcinogenesis - receptor activation, Dilated cardiomyopathy | D00076
D00076
|
Norepinephrine
| 2件: 22 22, 296 |
10 |
ADRB1
| 11件: Calcium signaling pathway Calcium signaling pathway, cGMP-PKG signaling pathway, cAMP signaling pathway, Neuroactive ligand-receptor interaction, Adrenergic signaling in cardiomyocytes, Gap junction, Regulation of lipolysis in adipocytes, Renin secretion, Salivary secretion, Chemical carcinogenesis - receptor activation, Dilated cardiomyopathy | D08443
D08443
|
Propranolol
| 6件: 6 6, 158, 167, 227, 278, 296 |
11 |
ADRB2
| 9件: Calcium signaling pathway Calcium signaling pathway, cGMP-PKG signaling pathway, cAMP signaling pathway, Neuroactive ligand-receptor interaction, Adrenergic signaling in cardiomyocytes, Regulation of lipolysis in adipocytes, Renin secretion, Salivary secretion, Chemical carcinogenesis - receptor activation | D00076
D00076
|
Norepinephrine
| 2件: 22 22, 296 |
12 |
ADRB2
| 9件: Calcium signaling pathway Calcium signaling pathway, cGMP-PKG signaling pathway, cAMP signaling pathway, Neuroactive ligand-receptor interaction, Adrenergic signaling in cardiomyocytes, Regulation of lipolysis in adipocytes, Renin secretion, Salivary secretion, Chemical carcinogenesis - receptor activation | D08443
D08443
|
Propranolol
| 6件: 6 6, 158, 167, 227, 278, 296 |
13 |
ADRB3
| 8件: Calcium signaling pathway Calcium signaling pathway, cGMP-PKG signaling pathway, Neuroactive ligand-receptor interaction, Thermogenesis, Regulation of lipolysis in adipocytes, Renin secretion, Salivary secretion, Chemical carcinogenesis - receptor activation | D00076
D00076
|
Norepinephrine
| 2件: 22 22, 296 |
14 |
ADRB3
| 8件: Calcium signaling pathway Calcium signaling pathway, cGMP-PKG signaling pathway, Neuroactive ligand-receptor interaction, Thermogenesis, Regulation of lipolysis in adipocytes, Renin secretion, Salivary secretion, Chemical carcinogenesis - receptor activation | D08443
D08443
|
Propranolol
| 6件: 6 6, 158, 167, 227, 278, 296 |
15 |
GABRA1
| 6件: Neuroactive ligand-receptor interaction Neuroactive ligand-receptor interaction, Retrograde endocannabinoid signaling, GABAergic synapse, Taste transduction, Morphine addiction, Nicotine addiction | D00549
D00549
|
Propofol
| 9件: 6 6, 21, 22, 34, 46, 70, 75, 98, 296 |
16 |
GABRA2
| 6件: Neuroactive ligand-receptor interaction Neuroactive ligand-receptor interaction, Retrograde endocannabinoid signaling, GABAergic synapse, Taste transduction, Morphine addiction, Nicotine addiction | D00549
D00549
|
Propofol
| 9件: 6 6, 21, 22, 34, 46, 70, 75, 98, 296 |
17 |
GABRA3
| 6件: Neuroactive ligand-receptor interaction Neuroactive ligand-receptor interaction, Retrograde endocannabinoid signaling, GABAergic synapse, Taste transduction, Morphine addiction, Nicotine addiction | D00549
D00549
|
Propofol
| 9件: 6 6, 21, 22, 34, 46, 70, 75, 98, 296 |
18 |
GABRA4
| 6件: Neuroactive ligand-receptor interaction Neuroactive ligand-receptor interaction, Retrograde endocannabinoid signaling, GABAergic synapse, Taste transduction, Morphine addiction, Nicotine addiction | D00549
D00549
|
Propofol
| 9件: 6 6, 21, 22, 34, 46, 70, 75, 98, 296 |
19 |
GABRA5
| 6件: Neuroactive ligand-receptor interaction Neuroactive ligand-receptor interaction, Retrograde endocannabinoid signaling, GABAergic synapse, Taste transduction, Morphine addiction, Nicotine addiction | D00549
D00549
|
Propofol
| 9件: 6 6, 21, 22, 34, 46, 70, 75, 98, 296 |
20 |
GABRA6
| 6件: Neuroactive ligand-receptor interaction Neuroactive ligand-receptor interaction, Retrograde endocannabinoid signaling, GABAergic synapse, Taste transduction, Morphine addiction, Nicotine addiction | D00549
D00549
|
Propofol
| 9件: 6 6, 21, 22, 34, 46, 70, 75, 98, 296 |
21 |
GABRB1
| 6件: Neuroactive ligand-receptor interaction Neuroactive ligand-receptor interaction, Retrograde endocannabinoid signaling, Serotonergic synapse, GABAergic synapse, Morphine addiction, Nicotine addiction | D00549
D00549
|
Propofol
| 9件: 6 6, 21, 22, 34, 46, 70, 75, 98, 296 |
22 |
GABRB2
| 6件: Neuroactive ligand-receptor interaction Neuroactive ligand-receptor interaction, Retrograde endocannabinoid signaling, Serotonergic synapse, GABAergic synapse, Morphine addiction, Nicotine addiction | D00549
D00549
|
Propofol
| 9件: 6 6, 21, 22, 34, 46, 70, 75, 98, 296 |
23 |
GABRB3
| 6件: Neuroactive ligand-receptor interaction Neuroactive ligand-receptor interaction, Retrograde endocannabinoid signaling, Serotonergic synapse, GABAergic synapse, Morphine addiction, Nicotine addiction | D00549
D00549
|
Propofol
| 9件: 6 6, 21, 22, 34, 46, 70, 75, 98, 296 |
24 |
GABRD
| 5件: Neuroactive ligand-receptor interaction Neuroactive ligand-receptor interaction, Retrograde endocannabinoid signaling, GABAergic synapse, Morphine addiction, Nicotine addiction | D00549
D00549
|
Propofol
| 9件: 6 6, 21, 22, 34, 46, 70, 75, 98, 296 |
25 |
GABRE
| 5件: Neuroactive ligand-receptor interaction Neuroactive ligand-receptor interaction, Retrograde endocannabinoid signaling, GABAergic synapse, Morphine addiction, Nicotine addiction | D00549
D00549
|
Propofol
| 9件: 6 6, 21, 22, 34, 46, 70, 75, 98, 296 |
26 |
GABRG1
| 5件: Neuroactive ligand-receptor interaction Neuroactive ligand-receptor interaction, Retrograde endocannabinoid signaling, GABAergic synapse, Morphine addiction, Nicotine addiction | D00549
D00549
|
Propofol
| 9件: 6 6, 21, 22, 34, 46, 70, 75, 98, 296 |
27 |
GABRG2
| 5件: Neuroactive ligand-receptor interaction Neuroactive ligand-receptor interaction, Retrograde endocannabinoid signaling, GABAergic synapse, Morphine addiction, Nicotine addiction | D00549
D00549
|
Propofol
| 9件: 6 6, 21, 22, 34, 46, 70, 75, 98, 296 |
28 |
GABRG3
| 5件: Neuroactive ligand-receptor interaction Neuroactive ligand-receptor interaction, Retrograde endocannabinoid signaling, GABAergic synapse, Morphine addiction, Nicotine addiction | D00549
D00549
|
Propofol
| 9件: 6 6, 21, 22, 34, 46, 70, 75, 98, 296 |
29 |
GABRP
| 5件: Neuroactive ligand-receptor interaction Neuroactive ligand-receptor interaction, Retrograde endocannabinoid signaling, GABAergic synapse, Morphine addiction, Nicotine addiction | D00549
D00549
|
Propofol
| 9件: 6 6, 21, 22, 34, 46, 70, 75, 98, 296 |
30 |
NR3C1
| 1件: Neuroactive ligand-receptor interaction Neuroactive ligand-receptor interaction | D00292
D00292
|
Dexamethasone
| 2件: 296 296, 299 |
31 |
NR3C1
| 1件: Neuroactive ligand-receptor interaction Neuroactive ligand-receptor interaction | D00407
D00407
|
Methylprednisolone
| 1件: 296 296 |
32 |
NR3C1
| 1件: Neuroactive ligand-receptor interaction Neuroactive ligand-receptor interaction | D00472
D00472
|
Prednisolone
| 3件: 296 296, 299, 300 |
33 |
PPARA
| 10件: PPAR signaling pathway PPAR signaling pathway, cAMP signaling pathway, Adipocytokine signaling pathway, Glucagon signaling pathway, Insulin resistance, Non-alcoholic fatty liver disease, Alcoholic liver disease, Hepatitis C, Chemical carcinogenesis - receptor activation, Diabetic cardiomyopathy | D01366
D01366
|
Bezafibrate
| 7件: 20 20, 93, 94, 160, 296, 316, 324 |
34 |
GABRQ
| 5件: Neuroactive ligand-receptor interaction Neuroactive ligand-receptor interaction, Retrograde endocannabinoid signaling, GABAergic synapse, Morphine addiction, Nicotine addiction | D00549
D00549
|
Propofol
| 9件: 6 6, 21, 22, 34, 46, 70, 75, 98, 296 |
35 |
PTGS2
| 22件: Arachidonic acid metabolism Arachidonic acid metabolism, Metabolic pathways, NF-kappa B signaling pathway, VEGF signaling pathway, C-type lectin receptor signaling pathway, IL-17 signaling pathway, TNF signaling pathway, Retrograde endocannabinoid signaling, Serotonergic synapse, Ovarian steroidogenesis, Oxytocin signaling pathway, Regulation of lipolysis in adipocytes, Alzheimer disease, Pathways of neurodegeneration - multiple diseases, Leishmaniasis, Human cytomegalovirus infection, Human papillomavirus infection, Kaposi sarcoma-associated herpesvirus infection, Pathways in cancer, Chemical carcinogenesis - DNA adducts, MicroRNAs in cancer, Small cell lung cancer | D00969
D00969
|
Meloxicam
| 4件: 46 46, 49, 271, 296 |
36 |
SLC10A1
| 2件: Bile secretion Bile secretion, Hepatitis B | D10951
D10951
|
Maralixibat
| 3件: 296 296, 297, 338 |
37 |
SLC10A2
| 1件: Bile secretion Bile secretion | D10951
D10951
|
Maralixibat
| 3件: 296 296, 297, 338 |
38 |
SLC10A2
| 1件: Bile secretion Bile secretion | D11716
D11716
|
Odevixibat
| 3件: 296 296, 297, 338 |
39 |
MS4A1
| 1件: Hematopoietic cell lineage Hematopoietic cell lineage | D02994
D02994
|
Rituximab
| 3件: 296 296, 300, 331 |
40 |
KEAP1
| 6件: Ubiquitin mediated proteolysis Ubiquitin mediated proteolysis, Parkinson disease, Pathways in cancer, Chemical carcinogenesis - reactive oxygen species, Hepatocellular carcinoma, Fluid shear stress and atherosclerosis | D03846
D03846
|
Dimethyl fumarate
| 5件: 13 13, 49, 51, 86, 296 |
41 |
NR1H4
| 1件: Bile secretion Bile secretion | D00734
D00734
|
Ursodeoxycholic acid
| 2件: 296 296, 299 |
42 |
NR1H4
| 1件: Bile secretion Bile secretion | D09360
D09360
|
Obeticholic acid
| 1件: 296 296 |